COVID-19 has mixed effect on Aspen Pharmacare’s bottom line

Organisation: Position: Deadline Date: Location:

Drugmaker Aspen Pharmacare has maintained its profit forecast for its year to end-June, as the COVID-19 pandemic has a mixed effect on the group and continues to generate uncertainty, reports Business Day. Elevated demand for anaesthetics in parts of Europe towards the latter part of the 10-month period to end-April, has offset the expected decline in the Chinese business brought about by the postponement of elective surgeries and less frequent haemodialysis treatment of patients, the group said.

“Stockpiling of everyday healthcare products and advanced filling of prescriptions by consumers in response to the COVID-19 pandemic has had a positive impact on the Regional Brands business,” the group said.

“This has led to overstocking in supply channels and in households, which we anticipate will result in decreased demand over the next few months as stock levels equalise.”

Full Business Day report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.